Will Lockwood retweeted
Today’s cancer treatments are built on decades of research—and sustained support. Former @NIH and NCI Director Dr. Harold Varmus reflects on why continued investment in NCI matters and gives researchers the opportunity to pursue new ideas and improve cancer prevention and treatment.
Will Lockwood retweeted
.@OhioStateMLAX dips into Canada for @Prep_Lacrosse's No. 74 junior Will Lockwood, a lefty middie for @lvilleblacrosse (N.J.) and @LANThunderJr. A speedy and slick two-way stalwart from British Columbia, Lockwood has a high ceiling and is expected to have a big spring.
Another new paper from the lab. Great collaboration with @MLadanyi lab investigating the mechanisms of resistance to TKIs in METex14 driven cancers. nature.com/articles/s41698-0…
New paper from PhD student Jana in the lab about an unexpected finding that has major implications in the fidelity of CRISPR screens! nature.com/articles/s42003-0…
New review from our group on the paradoxical role of increased ERK signalling as a vulnerability in cancer cells: link.springer.com/article/10…
Will Lockwood retweeted
As the high school approaches we are back with our @QCollarOfficial National High School Preseason Rankings!
@lvilleblacrosse takes the top spot in the first Top 2⃣5⃣ this spring. (via @dkaplan46)
🔗 insidelacrosse.com/article/q…
Will Lockwood retweeted
.@IASLC’s BaTS Committee review spotlights key advances in NSCLC research and outlines future areas that could improve survival and lead to new curative options for advanced disease. bit.ly/3WWdSy7
Will Lockwood retweeted
This week, we profile an Oncogene publication by the Lockwood lab at @BCCancer!
"This study addresses one of the central challenges in #LungCancer treatment: why tumors often relapse despite initial responses to targeted therapies," says Dr. Lockwood.
🧐 bit.ly/46fSbig
Latest from the lab in collaboration with the Bennewith and Dedhar labs @BCCancer and Ladanyi lab @MSKCancerCenter. Graduate student Rocky Shi demonstrates the importance of ILK in mediating tolerance to EGFR-targeted therapy in lung cancer. nature.com/articles/s41388-0…
This work was funded by @SRC_CRS which provided the opportunity to get this project off the ground and opening new areas of investigation into targeting ILK to prevent drug resistance in lung cancer patients.
2
73
Will Lockwood retweeted
Trump’s Liberation Day speech is filled with misinformation. The USA has higher tariff & non-tariff trade barriers than 68 other nations according to @Heritage.
New review from MSc student Sarah in the lab:
MET Activation in Lung Cancer and Response to Targeted Therapies mdpi.com/3136962 #mdpicancers via @Cancers_MDPI
1
80
Will Lockwood retweeted
Congratulations to the chairs of the @IASLC #HTTR24 meeting - fantastic faculty and content. Engaging. Amazing faculty list. Hope it becomes a regular occurrence! Amazing job by Drs. @WWL_18 @CespedesMontse @aliceb_phd and Kenichi Suda!
Will Lockwood retweeted
Tomorrow, 7/31, is your last chance to submit your abstract for #HTTR24! Share your groundbreaking research & contribute to the future of #lungcancer therapy, and our understanding/treatment of drug tolerance & resistance in #NSCLC. Submit Yours Now: bit.ly/HTTR24AS #LCSM
New paper from MD/PhD student Peiyao in the lab investigating the unique features within lung cancer patients who formerly smoked and how this impacts tumor biology and clinical outcomes: translational-medicine.biome…

















